572 related articles for article (PubMed ID: 37932756)
1. Precision medicine in nasopharyngeal carcinoma: comprehensive review of past, present, and future prospect.
Siak PY; Heng WS; Teoh SSH; Lwin YY; Cheah SC
J Transl Med; 2023 Nov; 21(1):786. PubMed ID: 37932756
[TBL] [Abstract][Full Text] [Related]
2. Epstein-Barr virus infection and nasopharyngeal carcinoma.
Tsao SW; Tsang CM; Lo KW
Philos Trans R Soc Lond B Biol Sci; 2017 Oct; 372(1732):. PubMed ID: 28893937
[TBL] [Abstract][Full Text] [Related]
3. Updates on Epstein-Barr Virus (EBV)-Associated Nasopharyngeal Carcinoma: Emphasis on the Latent Gene Products of EBV.
Ahmed N; Abusalah MAHA; Farzand A; Absar M; Yusof NY; Rabaan AA; AlSaihati H; Alshengeti A; Alwarthan S; Alsuwailem HS; Alrumaih ZA; Alsayyah A; Yean CY
Medicina (Kaunas); 2022 Dec; 59(1):. PubMed ID: 36676626
[TBL] [Abstract][Full Text] [Related]
4. Progression of understanding for the role of Epstein-Barr virus and management of nasopharyngeal carcinoma.
Nakanishi Y; Wakisaka N; Kondo S; Endo K; Sugimoto H; Hatano M; Ueno T; Ishikawa K; Yoshizaki T
Cancer Metastasis Rev; 2017 Sep; 36(3):435-447. PubMed ID: 28819752
[TBL] [Abstract][Full Text] [Related]
5. Detection of methylation status of Epstein-Barr virus DNA C promoter in the diagnosis of nasopharyngeal carcinoma.
Zheng XH; Wang RZ; Li XZ; Zhou T; Zhang JB; Zhang PF; Lu LX; Jia WH
Cancer Sci; 2020 Feb; 111(2):592-600. PubMed ID: 31834989
[TBL] [Abstract][Full Text] [Related]
6. Translational genomics of nasopharyngeal cancer.
Tsang CM; Lui VWY; Bruce JP; Pugh TJ; Lo KW
Semin Cancer Biol; 2020 Apr; 61():84-100. PubMed ID: 31521748
[TBL] [Abstract][Full Text] [Related]
7. Epstein-Barr virus BALF3 mediates genomic instability and progressive malignancy in nasopharyngeal carcinoma.
Chiu SH; Wu CC; Fang CY; Yu SL; Hsu HY; Chow YH; Chen JY
Oncotarget; 2014 Sep; 5(18):8583-601. PubMed ID: 25261366
[TBL] [Abstract][Full Text] [Related]
8. Plasma Epstein-Barr virus DNA as a biomarker for nasopharyngeal carcinoma.
Chan KC
Chin J Cancer; 2014 Dec; 33(12):598-603. PubMed ID: 25418194
[TBL] [Abstract][Full Text] [Related]
9. The role of Epstein-Barr virus infection in the pathogenesis of nasopharyngeal carcinoma.
Tsang CM; Tsao SW
Virol Sin; 2015 Apr; 30(2):107-21. PubMed ID: 25910483
[TBL] [Abstract][Full Text] [Related]
10. Association between Antibody Responses to Epstein-Barr Virus Glycoproteins, Neutralization of Infectivity, and the Risk of Nasopharyngeal Carcinoma.
Zhu QY; Kong XW; Sun C; Xie SH; Hildesheim A; Cao SM; Zeng MS
mSphere; 2020 Dec; 5(6):. PubMed ID: 33268566
[TBL] [Abstract][Full Text] [Related]
11. Genome-Wide Analysis of 18 Epstein-Barr Viruses Isolated from Primary Nasopharyngeal Carcinoma Biopsy Specimens.
Tu C; Zeng Z; Qi P; Li X; Yu Z; Guo C; Xiong F; Xiang B; Zhou M; Gong Z; Liao Q; Yu J; He Y; Zhang W; Li X; Li Y; Li G; Xiong W
J Virol; 2017 Sep; 91(17):. PubMed ID: 28637758
[TBL] [Abstract][Full Text] [Related]
12. Clinical utility of Epstein-Barr virus DNA and other liquid biopsy markers in nasopharyngeal carcinoma.
Tan R; Phua SKA; Soong YL; Oon LLE; Chan KS; Lucky SS; Mong J; Tan MH; Lim CM
Cancer Commun (Lond); 2020 Nov; 40(11):564-585. PubMed ID: 32989921
[TBL] [Abstract][Full Text] [Related]
13. Clinical utility of circulating Epstein-Barr virus DNA analysis for the management of nasopharyngeal carcinoma.
Fung SY; Lam JW; Chan KC
Chin Clin Oncol; 2016 Apr; 5(2):18. PubMed ID: 27121878
[TBL] [Abstract][Full Text] [Related]
14. Comparison of Epstein-Barr Virus Serological Tools for the Screening and Risk Assessment of Nasopharyngeal Carcinoma: a Large Population-based Study.
Guo J; Cui Z; Zheng Y; Li X; Chen Y
Pathol Oncol Res; 2020 Oct; 26(4):2185-2190. PubMed ID: 32222897
[TBL] [Abstract][Full Text] [Related]
15. Regulation of DNA Damage Signaling and Cell Death Responses by Epstein-Barr Virus Latent Membrane Protein 1 (LMP1) and LMP2A in Nasopharyngeal Carcinoma Cells.
Wasil LR; Wei L; Chang C; Lan L; Shair KH
J Virol; 2015 Aug; 89(15):7612-24. PubMed ID: 25972552
[TBL] [Abstract][Full Text] [Related]
16. Natural Variations in BRLF1 Promoter Contribute to the Elevated Reactivation Level of Epstein-Barr Virus in Endemic Areas of Nasopharyngeal Carcinoma.
Zhang JB; Huang SY; Wang TM; Dong SQ; He YQ; Zheng XH; Li XZ; Wang F; Jianbing M; Jia WH
EBioMedicine; 2018 Nov; 37():101-109. PubMed ID: 30420297
[TBL] [Abstract][Full Text] [Related]
17. Identification of genomic alterations in nasopharyngeal carcinoma and nasopharyngeal carcinoma-derived Epstein-Barr virus by whole-genome sequencing.
Tu C; Zeng Z; Qi P; Li X; Guo C; Xiong F; Xiang B; Zhou M; Liao Q; Yu J; Li Y; Li X; Li G; Xiong W
Carcinogenesis; 2018 Dec; 39(12):1517-1528. PubMed ID: 30102338
[TBL] [Abstract][Full Text] [Related]
18. Establishment of a nasopharyngeal carcinoma cell line capable of undergoing lytic Epstein-Barr virus reactivation.
Yip YL; Lin W; Deng W; Jia L; Lo KW; Busson P; Vérillaud B; Liu X; Tsang CM; Lung ML; Tsao SW
Lab Invest; 2018 Aug; 98(8):1093-1104. PubMed ID: 29769697
[TBL] [Abstract][Full Text] [Related]
19. Multiplex Epstein-Barr virus BALF2 genotyping detects high-risk variants in plasma for population screening of nasopharyngeal carcinoma.
Miller JA; Sahoo MK; Yamamoto F; Huang C; Wang H; Zehnder JL; Le QT; Pinsky BA
Mol Cancer; 2022 Jul; 21(1):154. PubMed ID: 35902864
[TBL] [Abstract][Full Text] [Related]
20. Circulating Epstein-Barr virus microRNAs miR-BART7 and miR-BART13 as biomarkers for nasopharyngeal carcinoma diagnosis and treatment.
Zhang G; Zong J; Lin S; Verhoeven RJ; Tong S; Chen Y; Ji M; Cheng W; Tsao SW; Lung M; Pan J; Chen H
Int J Cancer; 2015 Mar; 136(5):E301-12. PubMed ID: 25213622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
